GlassScriptPhysician profile
Carlos B C Lam
NPI 1366481590
$10,937.18
in general payments reported to CMS, 2019-2025
29 companies · $893 in 2025
The $893 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,363 · 2020: $1,570 · 2021: $2,385 · 2022: $2,383 · 2023: $1,529 · 2024: $813 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,561.58 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,735.49 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $669.11 | 2019-2025 | Trintellix |
| Horizon Therapeutics Plc | $649.07 | 2020-2023 | Krystexxa |
| Abbvie INC. | $409.80 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $390.20 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $388.18 | 2019-2023 | Mounjaro |
| Pfizer INC. | $268.44 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $265.54 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $224.28 | 2019-2023 | Myrbetriq |
| Sanofi-Aventis U.S. LLC | $221.31 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $165.53 | 2022 | |
| Amarin Pharma, INC. | $161.17 | 2020-2021 | |
| Glaxosmithkline, LLC. | $152.40 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $136.71 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $101.62 | 2021-2022 | |
| Insulet Corporation | $83.90 | 2019-2025 | Omnipod |
| Vanda Pharmaceuticals INC. | $65.49 | 2025 | Fanapt |
| Allergan, INC. | $60.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.82 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $37.12 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.83 | 2022 | |
| Axsome Therapeutics, INC. | $23.37 | 2023 | Auvelity |
| Mannkind Corporation | $21.48 | 2021 | |
| Radius Health, INC. | $17.73 | 2020 | |
| Vifor Pharma, INC. | $17.57 | 2019 | |
| Novo Nordisk INC | $17.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.48 | 2021 | |
| Abbott Laboratories | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.